Scarica l'app Stockscreener
12.81
11.10%
-1.60
Dopo l'orario di chiusura:
12.99
0.18
+1.41%
Precedente Chiudi:
$14.41
Aprire:
$14.4
Volume 24 ore:
1.76M
Relative Volume:
2.21
Capitalizzazione di mercato:
$1.06B
Reddito:
-
Utile/perdita netta:
-
Rapporto P/E:
-
EPS:
-
Flusso di cassa netto:
-
1 W Prestazione:
-9.34%
1M Prestazione:
+18.39%
6M Prestazione:
+0.00%
1 anno Prestazione:
+0.00%
Intervallo 1D:
$12.64
$14.40
Intervallo di 1 settimana:
$12.64
$14.69
Portata 52W:
$5.33
$14.69
Niagen Bioscience Inc Stock (NAGE) Company Profile
Nome
Niagen Bioscience Inc
Settore
Industria
Telefono
310-388-6706
Indirizzo
10900 WILSHIRE BLVD, LOS ANGELES
Confronta NAGE con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
NAGE
Niagen Bioscience Inc
|
12.81 | 1.06B | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.16 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
534.91 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
322.06 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
542.47 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
245.16 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Niagen Bioscience Inc Stock (NAGE) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-05-27 | Iniziato | Canaccord Genuity | Buy |
| 2022-08-16 | Downgrade | Oppenheimer | Outperform → Perform |
| 2022-08-11 | Downgrade | B. Riley Securities | Buy → Neutral |
| 2022-03-08 | Iniziato | ROTH Capital | Buy |
| 2019-10-16 | Iniziato | Oppenheimer | Outperform |
| 2019-02-14 | Iniziato | B. Riley FBR | Buy |
| 2017-11-27 | Ripresa | H.C. Wainwright | Buy |
| 2017-09-25 | Iniziato | Ladenburg Thalmann | Buy |
| 2017-01-03 | Iniziato | Rodman & Renshaw | Buy |
Mostra tutto
Niagen Bioscience Inc Borsa (NAGE) Ultime notizie
Niagen Bioscience (NASDAQ:NAGE) Shares Down 2.4%Should You Sell? - MarketBeat
Market Participants Recognise Niagen Bioscience, Inc.'s (NASDAQ:NAGE) Revenues Pushing Shares 29% Higher - simplywall.st
Niagen Bioscience (NASDAQ:NAGE) Lowered to "Buy" Rating by Wall Street Zen - MarketBeat
Niagen Bioscience (NASDAQ:NAGE) Price Target Raised to $16.00 - MarketBeat
Niagen Bioscience (NASDAQ:NAGE) Downgraded to Buy Rating by Wall Street Zen - Defense World
Niagen Bioscience (NASDAQ:NAGE) Sets New 12-Month High After Analyst Upgrade - MarketBeat
Niagen Bioscience to Participate in the BIO 2025 International C - GuruFocus
Niagen Bioscience to Participate in the BIO 2025 International Convention - Business Wire
Niagen Bioscience: High Conviction, High Expectations (NASDAQ:NAGE) - Seeking Alpha
Canaccord Genuity Group Issues Positive Forecast for Niagen Bioscience (NASDAQ:NAGE) Stock Price - Defense World
Niagen Bioscience (NAGE): Analyst Reaffirms Buy Rating and Incre - GuruFocus
Niagen Bioscience (NAGE) Gains Boost with Positive Clinical Resu - GuruFocus
Niagen study shows promise for Werner Syndrome treatment By Investing.com - Investing.com South Africa
Niagen Bioscience Announces First-Ever Peer-Reviewed Study Highlighting the Potential of Nicotinamide Riboside (NR) for Werner Syndrome, a Rare Genetic Disorder - Business Wire
Niagen Bioscience Announces First-Ever Peer-Reviewed Study Highl - GuruFocus
Niagen Bioscience stock rises following positive clinical study By Investing.com - Investing.com South Africa
Niagen Bioscience stock rises following positive clinical study - Investing.com Australia
Niagen study shows promise for Werner Syndrome treatment - Investing.com
Niagen Bioscience (NASDAQ:NAGE) Shares Gap Up After Analyst Upgrade - MarketBeat
Niagen Bioscience (NASDAQ:NAGE) Given New $23.00 Price Target at Roth Capital - MarketBeat
Niagen Bioscience (NASDAQ:NAGE) Stock Rating Lowered by Wall Street Zen - Defense World
Niagen Bioscience (NASDAQ:NAGE) Shares Gap Up on Analyst Upgrade - Defense World
Niagen Bioscience (NASDAQ:NAGE) Shares Gap Up Following Analyst Upgrade - Defense World
Roth Capital Reiterates “Buy” Rating for Niagen Bioscience (NASDAQ:NAGE) - Defense World
Niagen Bioscience (NASDAQ:NAGE) Reaches New 12-Month HighWhat's Next? - MarketBeat
Niagen Bioscience (NAGE) Target Price Raised to $23 by Roth Capi - GuruFocus
Niagen Bioscience (NAGE) Receives Price Target Boost from Roth Capital | NAGE Stock News - GuruFocus
What 4 Analyst Ratings Have To Say About Niagen Bioscience - Nasdaq
Niagen Bioscience (NAGE) Target Price Raised to $23 by Roth Capital | NAGE Stock News - GuruFocus
Niagen Bioscience (NASDAQ:NAGE) Trading 8.2% HigherShould You Buy? - MarketBeat
Niagen Bioscience Inc (NASDAQ:NAGE) Q1 2025 Earnings Call Transcript - MSN
Niagen Bioscience to Present at Oppenheimer's 25th Annual Consum - GuruFocus
Niagen Bioscience to Present at Oppenheimer's 25th Annual Consumer Growth and E-Commerce Conference | NAGE Stock News - GuruFocus
Niagen Bioscience to Present at Oppenheimer’s 25th Annual Consumer Growth and E-Commerce Conference - Business Wire
Niagen Bioscience (NASDAQ:NAGE) Reaches New 1-Year HighHere's What Happened - MarketBeat
Niagen Bioscience (NASDAQ:NAGE) Now Covered by Canaccord Genuity Group - MarketBeat
Niagen Bioscience (NASDAQ:NAGE) Coverage Initiated by Analysts at Canaccord Genuity Group - Defense World
Canaccord Genuity Initiates Coverage of Niagen Bioscience (NAGE) with Buy Recommendation - Nasdaq
Canaccord Genuity Initiates Niagen Bioscience at Buy With $13 Price Target - marketscreener.com
Canaccord starts Niagen Bioscience at Buy on ‘unique opportunity’ - TipRanks
Niagen Bioscience (NAGE) Receives Positive Outlook with $13 Pric - GuruFocus
Niagen Bioscience Inc Azioni (NAGE) Dati Finanziari
Non sono disponibili dati finanziari per Niagen Bioscience Inc (NAGE). Controlla altri titoli per ulteriori informazioni.
Reddito
Reddito netto
Flusso di cassa
EPS
Niagen Bioscience Inc Azioni (NAGE) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Lopez Carlos Luis | SVP, General Counsel |
Mar 07 '25 |
Buy |
7.86 |
273 |
2,146 |
2,251 |
| Jaksch Frank L Jr | Director |
Dec 13 '24 |
Option Exercise |
3.66 |
50,001 |
183,004 |
281,340 |
| Jaksch Frank L Jr | Director |
Dec 13 '24 |
Sale |
6.19 |
37,161 |
229,956 |
244,179 |
0.39%
0.42%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):